Kurma Partners Closes Biofund IV at $252 million to Advance ADCX-020 and Other Programs
Recovery of European Biotech Investment Sentiment and Fund Closing Background
Kurma Partners' Biofund IV closed at €215 million ($252 million). While this fell 14 % short of the €250 million target, it represents a 34 % increase over the previous Biofund III (€160 million). The achievement is notable because it occurred amid a European venture‑capital (VC) market strained by high interest rates and macro‑economic uncertainty. The fund formation underscores a polarization: early‑stage biotech financing remains challenging, yet capital continues to flow toward funds with proven leadership.
Innovative Drug Pipelines of Key Portfolio Companies
The fund has already invested in 11 startups and plans to allocate capital across roughly 20 promising companies. One of the marquee investments, Adcytherix, is developing the next‑generation antibody‑drug conjugate (ADC) ‘ADCX‑020’ and recently completed first‑patient dosing in a Phase I trial (NCT07238075) in solid‑tumor patients. Alveus Therapeutics, which targets obesity and metabolic disease, is pursuing the bifunctional fusion protein ‘ALV‑100’ with the aim of delivering weight‑loss efficacy and superior tolerability compared with existing therapies. Additionally, EvlaBio is advancing a preclinical monoclonal antibody candidate for the treatment of left ventricular hypertrophy (LVH) in chronic kidney disease (CKD) patients.
Diversification of Modalities and the Potential of Gene Therapy and Targeted Protein Degradation
Kurma Partners' portfolio extends beyond ADCs and obesity‑targeting peptides to include next‑generation gene therapies and targeted protein degradation (TPD) approaches. Nuevocor is leveraging its proprietary mechanobiology platform to develop an adeno‑associated virus (AAV) vector‑based gene therapy, ‘NVC‑001’, for LMNA‑related dilated cardiomyopathy, currently in Phase I/II trials. Laigo Bio of the Netherlands is advancing preclinical programs that use its SureTACs™ platform to selectively eliminate membrane proteins that drive cancer and autoimmune diseases. Elkedonia is creating a small‑molecule inhibitor of the neuroplasticity regulator Elk1, positioning itself to reshape the treatment‑resistant depression market.
Institutional Investor Collaboration Framework and Disruptive Impact on the Global Market
Bpifrance, Australia’s CSL Limited, the European Investment Fund (EIF), and parent company Eurazeo SE participated as cornerstone investors, substantially enhancing the fund’s credibility. Their involvement reinforces an end‑to‑end support system that translates academic basic‑science discoveries into globally competitive companies. Building on Medicxi’s €500 million fund and Jeito Capital’s €1 billion mega‑fund closures, this result signals Europe’s emergence as a central hub for global drug development. Ultimately, the fund will serve as a catalyst for long‑term investment needed to advance innovative therapies from preclinical stages through clinical entry, delivering breakthroughs that address unmet medical needs.
The final close of the $252 million Biofund IV, together with Medicxi’s €500 million fund, demonstrates the stability of institutional capital inflows into Europe and provides a short‑term relief to financing pressures faced by early‑stage startups. Alveus’s clinical‑stage obesity‑treatment pipeline ALV‑100 positions the company as a key competitor in a global obesity‑therapy market projected to reach $100 billion by 2030, thereby enhancing mid‑to‑long‑term exit potential. Moreover, the entry of diversified modalities—Nuevocor’s gene therapy NVC‑001 (Phase I/II) and Adcytherix’s ADCX‑020 (Phase I)—boosts the commercial viability of next‑generation targeted therapies and drives demand for clinical‑development talent across the sector. In the longer term, preclinical support for core technologies such as Elkedonia’s Elk1 inhibitor and Laigo Bio’s targeted protein degraders will maximize opportunities for technology licensing and M&A transactions with global big‑pharma partners.
Source: FierceBiotech (rss)